Nat Turner

Background

Nat Turner was born in Houston, Texas, and attended the Wharton School at the University of Pennsylvania, graduating cum laude in 2008 with a B.S. in Economics ¹². He began building businesses at age 12, starting with a reptile-breeding operation and web development company, eventually building over 380 websites before college ³.

In 2007, while still at Wharton, Turner co-founded Invite Media with classmate Zach Weinberg, building the industry’s first enterprise platform for buying and optimizing online display advertising in real-time ¹⁴. Google acquired Invite Media in June 2010 for a reported $70–$81 million ⁴⁵. Turner spent two years integrating the business into Google ¹.

In 2012, Turner and Weinberg co-founded Flatiron Health, a healthcare technology company focused on oncology data ¹. Turner was inspired by his cousin Brennan Simkins’s battle with AML, a rare form of leukemia ⁵. Flatiron Health built an electronic health record system and real-world evidence platform for cancer research. Roche, which had previously acquired a 12.6% equity stake, purchased all remaining shares in February 2018 for $1.9 billion on a fully diluted basis ⁶. Turner stated at the time of the acquisition: “Roche has been a tremendous partner to us over the past two years and shares our vision for building a learning healthcare platform in oncology ultimately designed to improve the lives of cancer patients” ⁶.

In November 2020, Turner led an investor group including D1 Capital Partners and Cohen Private Ventures to acquire Collectors Universe (parent of PSA, the leading trading card authentication service) for approximately $700 million ⁷. Turner became Chairman and CEO of Collectors Holdings, which was valued at $4.3 billion following a $100 million financing round in 2022 from D1 Capital, Cohen Private Ventures, and The Chernin Group ⁸. In November 2024, Turner was appointed to GameStop’s Board of Directors ⁹.

Turner has been an active angel investor since 2010, with over 250 startup investments ¹. Since mid-2020, he has invested primarily through Operator Partners, a self-funded venture fund he co-founded with Weinberg, Amit Avner, and Gil Shklarski (former CTO of Flatiron Health) ¹⁰¹⁰. Turner was named to Forbes 30 Under 30 in Healthcare ⁵.

Stated Thesis

Turner and Operator Partners publicly describe themselves as “operators funding operators,” emphasizing that their capital comes entirely from the partners’ own wealth with no outside LPs ¹⁰¹⁰. The fund writes $250K–$1M checks at pre-seed, seed, and Series A stages alongside lead investors, deliberately avoiding leading rounds or taking board seats ¹⁰¹⁰.

Turner has stated that he values a “bias for action” in founders, noting: “We call this a bias for action. So we have, that’s what we look for in people, you know, if you were to start a company, you have to have bias for action” ³. He has described his investment approach as long-term oriented: “I’m a big believer in taking the long road investing good things happen when people take kind of a longer, slower perspective. I’m a little bit of a tortoise as opposed to a hare” ³.

On idea generation, Turner has said: “When you see something in the world, like a problem you experience or a customer that needs help or something that you’re challenged by that you want it to be easier, you should write it down” ³. He encourages founders to prototype early rather than perfecting plans: “Just get started. The idea you start with will likely not be the idea you end with” ³.

Operator Partners positions itself as offering “on-demand operator support” — founders can go months without contact or request intensive help as needed, rather than receiving prescriptive board-level oversight ¹⁰.

Inferred Thesis

Based on 225 verified investments listed on Turner’s personal website (156 active, 36 acquired/IPO’d, 33 shut down) ¹¹, supplemented by Crunchbase (65 tracked investments) ¹² and Tracxn (144 investments via Operator Partners) ¹³. Turner claims 250+ total investments ¹; this analysis covers approximately 90% of his stated portfolio.

Sector distribution (225 verified investments, categorized from natsturner.com): - Healthcare / healthtech: 56 of 225 (25%) — Cedar, Headway, Cityblock, K Health, Carbon Health, Parsley Health, Galileo Health, Octave, Klara, Honeybee Health, Suki, Tomorrow Health, Ribbon Health, Uno Health, Connie Health, Enter Medicare, Rightway Healthcare, Hero Health, Particle Health, Nym Health, Verana Health, Gravie, Garner, Opencare, Small Door Vet, Wagmo, CareSwitch, Audicus, RxREVU, Gregor Diagnostics, Athae Bio, PhageNova Bio, Mythic Therapeutics, Mantra Bio, Notable Labs, Doctor Evidence, Assured Allies, SwipeSense, Bodily, Smylen, Color Genomics, Clover Health, Oscar Health, HIMS, Alto Neuroscience, Relay Therapeutics, Recursion Pharmaceuticals, C2i Genomics, Quartet Health, Recombine, Predilytics, Breakthrough, Elektra Labs, Dadi, Motion Clinical, Meddik - Fintech / financial services: 28 of 225 (12%) — Plaid, Ramp, Vise, Atom Finance, Cardless, Pillar Finance, Extra, Relay Payments, Metronome, Cascade, Petal, Fundera, Carver Edison, Causal, Lolli, Casa, Routable, Truework, Yotta, Lido, Daloopa, StarStreet, LifeLock, Panjiva, Blue Apron, Payoff, Slice, Wingspan - Enterprise software / developer tools: 28 of 225 (12%) — Flatfile, Glean, Immuta, mParticle, FullStory, Bubble, The Org, Almanac, Clause, Emissary, Imagen, Linear Labs, RightBound, Stoke Talent, Electric AI, Hyper Science, Plutoshift, Laika, Conduit, Antithesis, Kinta AI, Pico, Sage, Tatch, Lucky Sort, Predictive Edge, Timber, SolveBio - Consumer / marketplace: 26 of 225 (12%) — BarkBox, Misfits Market, Cometeer, Oura, Tonal, Philo, Clubhouse, LunchClub, Good Dog, Cure Hydration, Archer Roose, Sundays, Very Great, The Vendry, Welcome, Loupe, Supergreat, Twice, Milo.com, 42Floors, LiveLovely, Interior Define, The Citizenry, Spring, Good Uncle, Tasted Menu - Adtech / martech: 12 of 225 (5%) — AdZerk, Adentro, Vistar Media, Spinback, LocalResponse, ThinkNear, Adaptly, Arbor, ChatID, Cluster, Radar Labs, Kangaroo - Data / infrastructure: 11 of 225 (5%) — Chainalysis, David Energy, Common Networks, Resilience, Scope Security, Vital Software, Biofire Technologies, Keyo, Harvest, Remine, Tortoise - Collectibles / sports: 6 of 225 (3%) — CollX, Dibbs, PlayVS, StayTuned, Genamint, Ovation - Other / miscellaneous: 58 of 225 (26%) — remaining companies spanning workforce (Workrise, Drafted), HR (Wingspan), real estate (Atlas Lane), legal, education, and other sectors

Note: Categories are approximate; some companies span multiple sectors. Each counted once in its primary category.

Stage distribution: Turner invests primarily at seed and pre-seed stages, with some Series A and occasional Series B participation ¹⁰¹²¹⁴. Operator Partners’ stated focus is pre-seed through Series A with $250K–$1M checks ¹⁰. Signal NFX data shows verified rounds at Seed ($7.6M Flatfile, 2020), Series A ($11M Qualio, 2020), and Series B ($36M Cedar, 2018) ¹⁴.

Geographic concentration: Primarily US-based startups with New York City concentration, consistent with Turner’s own NYC base. Operator Partners has also made investments in Israel (5+ Israeli companies including Unit) ¹⁰.

Founder profile patterns: Turner has a documented pattern of backing very young and first-time founders — notably investing $100K in Vise when co-founder Samir Vasavada was a teenager ¹⁵. His emphasis on “bias for action” and prototyping over planning suggests a preference for execution-oriented founders over those with polished pitches ³³.

Co-investor patterns: Operator Partners invests alongside institutional leads rather than leading rounds. The fund partners with VCs to “accelerate due diligence” ¹⁰. Across portfolio companies, frequent co-investors include Thrive Capital, Accel, GV (Google Ventures), Andreessen Horowitz, and Spark Capital ¹⁶.

Notable pattern — healthcare dominance: Despite investing across many sectors, healthcare/healthtech represents Turner’s largest concentration at 25% of verified investments. This is consistent with his Flatiron Health background but extends far beyond oncology into mental health (Headway, Octave), primary care (Carbon Health, K Health), pharmacy (Honeybee Health, Zipdrug), insurance navigation (Rightway, Garner), and biotech (Recursion, Relay Therapeutics). His healthcare thesis appears to be “fix broken healthcare workflows with technology,” applied broadly.

Exit performance: 36 of 225 investments (16%) resulted in acquisitions or IPOs, including notable outcomes like BarkBox (IPO), Oscar Health (IPO), Clover Health (IPO), HIMS (IPO), Plaid (attempted $5.3B Visa acquisition, later valued at $13B+), Recursion Pharmaceuticals (IPO), Relay Therapeutics (IPO), Alto Neuroscience (IPO), and Troops (acquired by Salesforce) ¹¹. 33 of 225 (15%) are confirmed shut down ¹¹.

Portfolio

The following table represents a selection of 40 notable investments from Turner’s verified portfolio of 225+ companies ¹¹¹².

Note: Many entries marked “Early” and “~Year” indicate the investment stage and year could not be independently confirmed beyond the company’s presence on Turner’s portfolio page. Exact investment dates are not publicly disclosed for most angel investments. Entries with specific stages and years are confirmed via Signal NFX ¹⁴, Crunchbase ¹², or press coverage ¹⁷.

This table represents approximately 18% of Turner’s 225 verified investments. A comprehensive portfolio list is available at natsturner.com/investments ¹¹.

In Their Own Words

“I’m a big believer in taking the long road investing good things happen when people take kind of a longer, slower perspective. I’m a little bit of a tortoise as opposed to a hare.” — Nat Turner, How Leaders Lead podcast ³

“We call this a bias for action. So we have, that’s what we look for in people, you know, if you were to start a company, you have to have bias for action.” — Nat Turner, How Leaders Lead podcast ³

“Just get started. The idea you start with will likely not be the idea you end with.” — Nat Turner, How Leaders Lead podcast ³

“The most dangerous thing once you’ve become successful is not realizing your ideas are stupid.” — Nat Turner, How Leaders Lead podcast ³

“Have strong opinions, loosely held. Don’t get so entrenched in your opinions that they can’t evolve.” — Nat Turner, How Leaders Lead podcast ³

“A perfect plan executed tomorrow is worse than a halfway decent plan executed violently today.” — Nat Turner, How Leaders Lead podcast (paraphrasing a military general) ³

“When you see something in the world, like a problem you experience or a customer that needs help or something that you’re challenged by that you want it to be easier, you should write it down.” — Nat Turner, Penn Innovators in Business interview ³

“Roche has been a tremendous partner to us over the past two years and shares our vision for building a learning healthcare platform in oncology ultimately designed to improve the lives of cancer patients.” — Nat Turner, Roche press release on Flatiron Health acquisition, February 2018 ⁶

“There are very few things more powerful than nostalgia.” — Nat Turner on collector motivations, Wharton Magazine, Spring/Summer 2023 ²

What Founders Say

Florian Otto, Co-Founder and CEO of Cedar (patient financial engagement platform, Turner portfolio company), has stated that for general business guidance, Nat Turner is someone he goes to often, noting that Turner has deep experience in the healthcare technology business ¹⁸.

Samir Vasavada, Co-Founder and CEO of Vise (AI-powered wealth management), has described Turner and Weinberg as pivotal early backers. Vasavada has recounted that after facing numerous fundraising rejections, Turner and Weinberg provided Vise’s first $100,000 investment, which was the turning point that allowed the company to survive and continue development ¹⁵¹⁹.

Headway, the mental health platform valued at $2.3 billion, has acknowledged receiving early angel investment from the founders of Flatiron Health (Turner and Weinberg) among other influential healthcare company founders ¹⁶.

No additional independently sourced founder testimonials with verbatim quotes were found. Turner’s AngelList profile contains general testimonials describing him as “a highly respected entrepreneur and investor who supports the founders of his investments” and “an incredible entrepreneur and leader with a wealth of knowledge about building great companies,” but these could not be attributed to specific named founders ²⁰.

Sources